Multimedia Content
Call for phase 2 clinical trial
CuraVac is ready for a phase 2b demonstration of efficacy with the MG Targeted Active Therapy CV-MG02 and is looking to complete its financing.
Stephane’s story
How I came to develop and use the Targeted Active Therapy for Myasthenia Gravis.
Stephane’s story (short)
More than 25 years in less than 50 seconds.
Targeted Active Therapy explained
A 3 minute explanation of Active targeted Immunotherapy for autoimmune diseases.
Phase 2b clinical trial (short)
A very brief description of how the phase 2b clinical trial can demonstrate efficacy of our MG Targeted Active Therapy candidate
Carlos’ testimony
A patient’s testimony and point of view on our work.
The struggles of living with MG
What it means to live with Myasthenia Gravis and the side effects of the disease and its treatments in 30 seconds.
Self-Trial of the MG Therapeutic Vaccine
Why I decided to test the first version of the MG Targeted Active Therapy on myself and continue its development for all patients.
Professor Blalock’s revolutionary discovery
How research of a molecular theory lead to Active Targeted Immunotherapy for autoimmune diseases.
The story of a discovery and its development
An explanation of the concept of Active Targeted Immunotherapy, why they can work in humans, what it means to manufacture a human formulation, and why we are raising funds.
MG Therapeutic Vaccine on to Phase 2b
Why we developed a stronger formulation for the Phase 2b Clinical Trial.
A dog cured of Myasthenia Gravis
A dog cured of Myasthenia Gravis (60s)
